Precision Neuroscience raises $250M led by Pershing Square
Precision Neuroscience, a brain-computer interface company, raised $250M in Series D funding led by Pershing Square, bringing total capital to $430M. The company has completed 100+ patient procedures, received FDA clearance, and plans to expand clinical programs and commercialization efforts. Investors include ARK Invest and Mubadala Capital.
How this was made
The 30-second read
Why it matters
The funding strengthens the company's balance sheet, likely supporting a near‑term price uptick as investors price in growth potential.
Market read
A sizable capital raise for a niche neuro‑tech firm, signaling sector momentum and potential upside for related stocks.
What to watch
Potential competition from larger med‑tech firms and the timeline for FDA approvals.
Background
Precision Neuroscience announced a $250M Series D round led by Pershing Square, expanding its BCI platform.
Market effects
Boosts the brain‑computer interface sector with fresh capital and validation.
May attract more venture funding to U.S. neuro‑tech startups.
Highlights growing investor interest in neurotechnology worldwide.
Counterpoint
The raise could dilute existing shareholders and the technology may face regulatory hurdles.
Key entities
- companyPrecision Neuroscience Corporation
Brain‑computer interface developer raising $250M.
- investorPershing Square Inc.
Lead investor in the Series D round.
